These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34852220)

  • 1. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
    Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
    Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
    Stalnecker CA; Grover KR; Edwards AC; Coleman MF; Yang R; DeLiberty JM; Papke B; Goodwin CM; Pierobon M; Petricoin EF; Gautam P; Wennerberg K; Cox AD; Der CJ; Hursting SD; Bryant KL
    Cancer Res; 2022 Feb; 82(4):586-598. PubMed ID: 34921013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
    Ozkan-Dagliyan I; Diehl JN; George SD; Schaefer A; Papke B; Klotz-Noack K; Waters AM; Goodwin CM; Gautam P; Pierobon M; Peng S; Gilbert TSK; Lin KH; Dagliyan O; Wennerberg K; Petricoin EF; Tran NL; Bhagwat SV; Tiu RV; Peng SB; Herring LE; Graves LM; Sers C; Wood KC; Cox AD; Der CJ
    Cell Rep; 2020 Jun; 31(11):107764. PubMed ID: 32553168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
    Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
    Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
    Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
    Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.
    Wang X; Breuer J; Garbe S; Giordano F; Brossart P; Feldmann G; Bisht S
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
    Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
    Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.
    Waters AM; Khatib TO; Papke B; Goodwin CM; Hobbs GA; Diehl JN; Yang R; Edwards AC; Walsh KH; Sulahian R; McFarland JM; Kapner KS; Gilbert TSK; Stalnecker CA; Javaid S; Barkovskaya A; Grover KR; Hibshman PS; Blake DR; Schaefer A; Nowak KM; Klomp JE; Hayes TK; Kassner M; Tang N; Tanaseichuk O; Chen K; Zhou Y; Kalkat M; Herring LE; Graves LM; Penn LZ; Yin HH; Aguirre AJ; Hahn WC; Cox AD; Der CJ
    Cell Rep; 2021 Jun; 35(13):109291. PubMed ID: 34192548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
    Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.
    Bryant KL; Stalnecker CA; Zeitouni D; Klomp JE; Peng S; Tikunov AP; Gunda V; Pierobon M; Waters AM; George SD; Tomar G; Papke B; Hobbs GA; Yan L; Hayes TK; Diehl JN; Goode GD; Chaika NV; Wang Y; Zhang GF; Witkiewicz AK; Knudsen ES; Petricoin EF; Singh PK; Macdonald JM; Tran NL; Lyssiotis CA; Ying H; Kimmelman AC; Cox AD; Der CJ
    Nat Med; 2019 Apr; 25(4):628-640. PubMed ID: 30833752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.
    Diehl JN; Hibshman PS; Ozkan-Dagliyan I; Goodwin CM; Howard SV; Cox AD; Der CJ
    Adv Cancer Res; 2022; 153():101-130. PubMed ID: 35101228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical KRAS
    Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
    Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular mechanism underlying KRAS regulation on STK31 expression in pancreatic ductal adenocarcinoma.
    Liu Y; Tang SC; Li CH; To KF; Li B; Chan SL; Wong CH; Chen Y
    Cancer Sci; 2024 Oct; 115(10):3288-3304. PubMed ID: 39054797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.
    Diehl JN; Klomp JE; Snare KR; Hibshman PS; Blake DR; Kaiser ZD; Gilbert TSK; Baldelli E; Pierobon M; Papke B; Yang R; Hodge RG; Rashid NU; Petricoin EF; Herring LE; Graves LM; Cox AD; Der CJ
    J Biol Chem; 2021 Nov; 297(5):101335. PubMed ID: 34688654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.